PYCR1 inhibition in bone marrow stromal cells enhances bortezomib sensitivity in multiple myeloma cells by altering their metabolism
Recent Publication
An international research team with the participation of OA Univ.-Prof. Mag. DDr. Klaus Podar, Dr Osman Aksoy and OÄ PD Dr Sonia Vallet from the Department of Molecular Oncology and Haematology has found new ways to break through resistance in multiple myeloma. This form of blood cancer often remains incurable despite modern therapies because the cancer cells fight off drugs such as bortezomib. The researchers were able to show that a specific enzyme, PYCR1, plays an important role in this process. If PYCR1 is inhibited, metabolic processes in the cancer cells change - and they react more sensitively to the drug again. In laboratory models, the combination of PYCR1 blockade and bortezomib significantly reduced the tumour burden, which gives hope for new, more effective treatment strategies.
Oudaert, I., van den Broecke, L., Aksoy, O., Lind, J., Vallet, S., Van der Vreken, A., Ates, G., Massie, A., Maes, K., De Veirman, K., De Bruyne, E., Vanderkerken, K., Podar, K., & Menu, E. (2025). PYCR1 inhibition in bone marrow stromal cells enhances bortezomib sensitivity in multiple myeloma cells by altering their metabolism. Molecular Oncology. Advance online publication. https://doi.org/10.1002/1878-0261.70120
Dr. Osman Aksoy
Scientific Staff (PostDoc)
Department of Molecular Oncology and Hematology
OÄ PD Dr. Sonia Vallet
Department of Molecular Oncology and Hematology, Division of Internal Medicine 2 (University Hospital Krems)
OA Univ.-Prof. Mag. DDr. Klaus Podar
Head of
Department of Molecular Oncology and Hematology, Division of Internal Medicine 2 (University Hospital Krems)